RSPO2 gene amplification occurs in up to 6.5% and 21% of primary and advanced prostate cancers, respectively, and has a strong tendency to co-occur with FZD6 overexpression (Table 1, Figures S1–S4, [64,65,66]). The gene discussed is RSPO2; the disease is prostate carcinoma.